Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer - Top-Institutions - MDSpire

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

  • By

  • Agata Świętek

  • Joanna K. Strzelczyk

  • Dorota Hudy

  • Zenon P. Czuba

  • Karolina Snopek-Miśta

  • Mariusz Kryj

  • Katarzyna Kuśnierz

  • Marcin Zeman

  • Malgorzata Oczko-Wojciechowska

  • Daria Handkiewicz-Junak

  • Janusz Strzelczyk

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Prof. Kornel Gibiński Independent Public Central Clinical Hospital
    Prof. Kornel Gibiński Independent Public Central Clinical Hospital

    Warsaw, Mazowieckie

    Key Differentiators

    • Oncology

  • #2

    Medical University of Silesia in Katowice
    Medical University of Silesia in Katowice

    Katowice, Silesian Voivodeship

    Key Differentiators

    • Oncology

  • #3

    Maria Sklodowska-Curie National Research Institute of Oncology
    Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Mazowieckie

    Key Differentiators

    • Oncology

  • #4

    Department of Medical and Molecular Biology
    Department of Medical and Molecular Biology

    Zabrze, Silesian Voivodeship

    Key Differentiators

    • Oncology

  • #5

    Department of Microbiology and Immunology
    Department of Microbiology and Immunology

    Zabrze, Silesian Voivodeship

    Key Differentiators

    • Oncology

Original Source(s)

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

  • by Agata Świętek, Joanna K. Strzelczyk, Dorota Hudy, Zenon P. Czuba, Karolina Snopek-Miśta, Mariusz Kryj, Katarzyna Kuśnierz, Marcin Zeman, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Janusz Strzelczyk

  • July 2, 2026

Related Content

RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min